ホーム › 尿路上皮（移行上皮）癌 › テキサス › Dallas
Dallas、TXにおける尿路上皮（移行上皮）癌の臨床試験
Dallasとその周辺地域（約30マイル以内）の拠点で、尿路上皮（移行上皮）癌に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
被験者募集中第3相
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #89, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
被験者募集中第2相
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
被験者募集中観察研究
- UT Southwestern Medical Center, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Baylor, Scott and White Research Institute, Dallas
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- Parkland Health and Hospital System, Dallas
- UT Southwestern Medical Center, Dallas
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
被験者募集中第1相
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
被験者募集中第2/3相
- Research Site, Dallas
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
被験者募集中第1/2相
- Texas Oncology, P.A., Dallas
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
被験者募集中第2相
- Baylor Scott and White Research Institute, Dallas
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
被験者募集中第3相
- Research Site, Dallas
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- Texas Oncology - DFW, Dallas
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
被験者募集中
- UT Southwestern Medical Center, Dallas
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
被験者募集中観察研究
- UT Southwestern Medical Center, Dallas
Bladder Cancer Screening Trial
被験者募集中
- University of Texas Southwestern Medical Center, Dallas
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
被験者募集中健康なボランティア歓迎
- University of Texas Southwestern Medical Center, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Dallas
他の都市における尿路上皮（移行上皮）癌の試験
- Nashville, TN23件の研究
- New York City, NY22件の研究
- Houston, TX19件の研究
- Edison, NJ18件の研究
- Los Angeles, CA17件の研究
- Queens, NY15件の研究
- Chicago, IL14件の研究
- Arlington, VA12件の研究
- Boston, MA11件の研究
- San Antonio, TX11件の研究
- Austin, TX10件の研究
- Orange, CA10件の研究
Dallasにおける他の研究
- 乳がん55件の研究
- 非小細胞肺癌52件の研究
- 転移性癌42件の研究
- 心不全42件の研究
- がん（全種類）37件の研究
- 前立腺がん36件の研究
- 大腸癌33件の研究
- 肥満症30件の研究
- 卵巣がん28件の研究
- 肺がん27件の研究
- 膀胱癌27件の研究
- 子宮内膜がん24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。